Marc Riviere | General Partner
T.V.M. Life Science Management Gmbh

Marc Riviere, General Partner, T.V.M. Life Science Management Gmbh

An experienced executive with a track record in successfully building and managing clinical programs, Marc’s expertise encompasses all aspects of drug development in different clinical indications from pre-clinical development to post marketing surveillance. At TVM Capital Life Science, he focuses on evaluation of deal opportunities and investment management for therapeutics. He also works closely with the firm’s strategic partner Eli Lilly & Co. and its drug development division Chorus. He also serves on the board of publicly listed (Euronext) Cerenis Therapeutics, Toulouse, France, Ann Arbor, USA. Prior to joining TVM Capital Life Science, Marc was Vice-President, Axcan Pharma Inc., in charge of Clinical Development, Medical Affairs and Pharmacovigilance and a member of the Axcan Licensing Committee. He also served as Senior Vice President, Clinical Development at Caprion Pharmaceuticals, Chief Medical Officer for Bioniche Life Sciences Inc., Managing Director of Xenon Genetics Inc., Vice President of Clinical Affairs, Aeterna Labs and Executive Vice President and Regional Director, Quintiles Inc. He was also member of the Guideline Review Committee of the Canadian Co-ordination Office of Health Technology Assessment. Marc received his Tropical Disease Medicine Certification from Université Bordeaux II, France and Medicine Doctorate from Université Paul Sabatier, Toulouse, France, and has over fifty publications and scientific communications to his credit.


Day 2 Orphan 15th Nov @ 13:40

Investor panel: Hear how different investors decide on who and what they invest in, and why

  • What stage do they invest in biotechs and why?
  • How much clinical data do they need to demonstrate?
  • What terms do VCs look for to invest?
  • What could a biotech demonstrate to investors earlier to gain their support?

back to speakers